Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.

Harbeck N, Gluz O, Christgen M, Braun M, Kummel S, Potenberg J, Aktas B, Schumacher C, Forstbauer H, Augustin D, Kraemer S, Just M, Tio J, Kleine-Tebbe A, Liedtke C, Kates R, Hofmann D, Wuerstlein R, Kreipe H, Nitz U